Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

INTRODUCTION: Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC) patients. Therefore, the aim of this study was to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203315/
https://www.ncbi.nlm.nih.gov/pubmed/34136409
http://dx.doi.org/10.3389/fonc.2021.684073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203315/
https://www.ncbi.nlm.nih.gov/pubmed/34136409
http://dx.doi.org/10.3389/fonc.2021.684073

Ejemplares similares